Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.
Khalil A, Würthwein G, Golitsch J, Hempel G, Fobker M, Gerss J, Möricke A, Zimmermann M, Smisek P, Zucchetti M, Nath C, Attarbaschi A, Von Stackelberg A, Gökbuget N, Rizzari C, Conter V, Schrappe M, Boos J, Lanvers-Kaminsky C. Khalil A, et al. Among authors: smisek p. Haematologica. 2022 Jan 1;107(1):49-57. doi: 10.3324/haematol.2020.258525. Haematologica. 2022. PMID: 33299233 Free PMC article.
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Kaspers GJ, Zimmermann M, Reinhardt D, Gibson BE, Tamminga RY, Aleinikova O, Armendariz H, Dworzak M, Ha SY, Hasle H, Hovi L, Maschan A, Bertrand Y, Leverger GG, Razzouk BI, Rizzari C, Smisek P, Smith O, Stark B, Creutzig U. Kaspers GJ, et al. Among authors: smisek p. J Clin Oncol. 2013 Feb 10;31(5):599-607. doi: 10.1200/JCO.2012.43.7384. Epub 2013 Jan 14. J Clin Oncol. 2013. PMID: 23319696 Clinical Trial.
The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01.
Creutzig U, Zimmermann M, Dworzak MN, Gibson B, Tamminga R, Abrahamsson J, Ha SY, Hasle H, Maschan A, Bertrand Y, Leverger G, von Neuhoff C, Razzouk B, Rizzari C, Smisek P, Smith OP, Stark B, Reinhardt D, Kaspers GL. Creutzig U, et al. Among authors: smisek p. Haematologica. 2014 Sep;99(9):1472-8. doi: 10.3324/haematol.2014.104182. Epub 2014 Apr 24. Haematologica. 2014. PMID: 24763401 Free PMC article. Clinical Trial.
Therapeutic Drug Monitoring of Asparaginase Activity-Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial.
Lanvers-Kaminsky C, Rüffer A, Würthwein G, Gerss J, Zucchetti M, Ballerini A, Attarbaschi A, Smisek P, Nath C, Lee S, Elitzur S, Zimmermann M, Möricke A, Schrappe M, Rizzari C, Boos J. Lanvers-Kaminsky C, et al. Among authors: smisek p. Ther Drug Monit. 2018 Feb;40(1):93-102. doi: 10.1097/FTD.0000000000000472. Ther Drug Monit. 2018. PMID: 29210976 Clinical Trial.
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.
Rizzari C, Lanvers-Kaminsky C, Valsecchi MG, Ballerini A, Matteo C, Gerss J, Wuerthwein G, Silvestri D, Colombini A, Conter V, Biondi A, Schrappe M, Moericke A, Zimmermann M, von Stackelberg A, Linderkamp C, Frühwald MC, Legien S, Attarbaschi A, Reismüller B, Kasper D, Smisek P, Stary J, Vinti L, Barisone E, Parasole R, Micalizzi C, Zucchetti M, Boos J. Rizzari C, et al. Among authors: smisek p. Haematologica. 2019 Sep;104(9):1812-1821. doi: 10.3324/haematol.2018.206433. Epub 2019 Jan 31. Haematologica. 2019. PMID: 30705097 Free PMC article. Clinical Trial.
Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study.
Würthwein G, Lanvers-Kaminsky C, Gerss J, Möricke A, Zimmermann M, Stary J, Smisek P, Attarbaschi A, Nath C, Zucchetti M, Rizzari C, Schrappe M, Boos J; AIEOP-BFM ALL 2009 Asparaginase Working Party. Würthwein G, et al. Among authors: smisek p. Ther Drug Monit. 2020 Jun;42(3):435-444. doi: 10.1097/FTD.0000000000000727. Ther Drug Monit. 2020. PMID: 32022785
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data.
Würthwein G, Lanvers-Kaminsky C, Siebel C, Gerß J, Möricke A, Zimmermann M, Stary J, Smisek P, Schrappe M, Rizzari C, Zucchetti M, Hempel G, Wicha SG, Boos J; AIEOP-BFM ALL 2009 Asparaginase Working Party. Würthwein G, et al. Among authors: smisek p. Eur J Drug Metab Pharmacokinet. 2021 Mar;46(2):289-300. doi: 10.1007/s13318-021-00670-8. Epub 2021 Feb 17. Eur J Drug Metab Pharmacokinet. 2021. PMID: 33595793 Free PMC article. Clinical Trial.
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS.
Bertrums EJM, Zwaan CM, Hasegawa D, De Haas V, Reinhardt DN, Locatelli F, De Moerloose B, Dworzak M, Buijs A, Smisek P, Kolenova A, Pronk CJ, Klusmann JH, Carboné A, Ferster A, Antoniou E, Meshinchi S, Raimondi SC, Niemeyer CM, Hasle H, Van den Heuvel-Eibrink MM, Goemans BF. Bertrums EJM, et al. Among authors: smisek p. Haematologica. 2022 Mar 1;107(3):759-764. doi: 10.3324/haematol.2021.279507. Haematologica. 2022. PMID: 34854279 Free PMC article. No abstract available.
Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach.
Siebel C, Lanvers-Kaminsky C, Alten J, Smisek P, Nath CE, Rizzari C, Boos J, Würthwein G. Siebel C, et al. Among authors: smisek p. Eur J Drug Metab Pharmacokinet. 2022 Mar;47(2):187-198. doi: 10.1007/s13318-021-00741-w. Epub 2021 Dec 8. Eur J Drug Metab Pharmacokinet. 2022. PMID: 34878584 Free PMC article. Clinical Trial.
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
Conter V, Valsecchi MG, Cario G, Zimmermann M, Attarbaschi A, Stary J, Niggli F, Dalla Pozza L, Elitzur S, Silvestri D, Locatelli F, Möricke A, Engstler G, Smisek P, Bodmer N, Barbaric D, Izraeli S, Rizzari C, Boos J, Buldini B, Zucchetti M, von Stackelberg A, Matteo C, Lehrnbecher T, Lanvers-Kaminsky C, Cazzaniga G, Gruhn B, Biondi A, Schrappe M. Conter V, et al. Among authors: smisek p. J Clin Oncol. 2024 Mar 10;42(8):915-926. doi: 10.1200/JCO.23.01388. Epub 2023 Dec 14. J Clin Oncol. 2024. PMID: 38096462
28 results